New Age Alpha Advisors LLC Purchases Shares of 24,838 Zoetis Inc. (NYSE:ZTS)

New Age Alpha Advisors LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,838 shares of the company’s stock, valued at approximately $4,047,000.

Several other large investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its stake in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 166 shares during the last quarter. Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis during the fourth quarter worth about $44,000. Finally, Asset Planning Inc purchased a new position in shares of Zoetis in the 4th quarter valued at approximately $58,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $163.03 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company’s fifty day moving average price is $166.40 and its 200 day moving average price is $174.67. The company has a market capitalization of $73.00 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ZTS. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.